Chemistry, Pharmaceutical and Medicinal Chemistry, Pharmacology, Biochemistry and Molecular Biology

被引:0
作者
Soniya, Naik [1 ,2 ]
Soumya, Vasu [1 ]
Shivlingrao, Mamle Desai [1 ]
Manickavasagam, M. [3 ]
Meeramol, Chellappan [1 ]
机构
[1] Sri Ramachandra Inst Higher Educ & Res, Sri Ramachandra Fac Pharm, Dept Pharmaceut Chem, Chennai 600116, India
[2] PESs Rajaram & Tarabai Bandekar Coll Pharm, Dept Pharmaceut Chem, Ponda 403401, Goa, India
[3] Sri Ramachandra Inst Higher Educ & Res, Dept Oncol, SRMC & RI, Chennai 600116, India
关键词
Quinolin-2-one; hybridization; anticancer; heterocyclic; linomide; chalcone; ANTICANCER ACTIVITY; HYBRID COMPOUNDS; DERIVATIVES; DESIGN; DRUGS; DISCOVERY; HYBRIDIZATION; CYTOTOXICITY; INHIBITORS; CHALCONES;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
he statistical data related to cancer in recent years has shown a great increase in the number of cases and is likely to further increase in the future. Even after seeking thorough knowledge on the aetiology of cancer and related disorders and attempting to cure it by various methods like gene therapy, T cell therapy, chemotherapy, surgery, hormone therapy, and photodynamic therapy, there has always been disappointment concerning the survival rate. Hence, there is still a great urge for the discovery of novel drugs for the treatment of cancer. Chemotherapy being one of the widely used methods, several drug entities possessing anticancer properties are already in the market but none of them is known to show good efficacy which necessitates researchers to design newer drugs for the treatment of cancer. The urge to synthesize novel anticancer entities directed researchers towards molecular hybridization as one of the novel methods for designing newer drugs. Literature reveals wide research carried out on quinolin-2-one hybrids, possessing anticancer properties through different mechanisms. Tipifarnib and Dovitinib are quinolin-2-one hybrids used to treat cancer, possessing imidazole and benzimidazole heterocyclic rings. Different heterocyclic scaffolds such as pyrone, pyrrole, pyrimidine, pyridine, thiazole, and pyrazole in combination with heterocyclic quinolin-2-one have shown high potential to become lead for newer anticancer agents with better and wider therapeutic properties and lesser side effects. The current review presents information on the different quinolin-2-one hybrids and their effect on different cancer cell lines. It also imparts knowledge of the structural requirements for designing novel anticancer agents.
引用
收藏
页数:17
相关论文
共 88 条
  • [71] Saeed A.M., 2020, Open J. Med. Chem, V10, P1, DOI DOI 10.4236/OJMC.2020.101001
  • [72] Anticancer activity of novel Schiff bases and azo dyes derived from 3-amino-4-hydroxy-2-Hpyrano[3,2-c]quinoline-2,5(6H)-dione
    Saeed, Abdeltawab Mohamed
    AlNeyadi, Shaikha S.
    Abdou, Ibrahim M.
    [J]. HETEROCYCLIC COMMUNICATIONS, 2020, 26 (01) : 192 - 205
  • [73] Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets
    Satija, Garvit
    Sharma, Barkha
    Madan, Anish
    Iqubal, Ashif
    Shaquiquzzaman, Mohammad
    Akhter, Mymoona
    Parvez, Suhel
    Khan, Mohammad Ahmed
    Alam, Mohammad Mumtaz
    [J]. JOURNAL OF HETEROCYCLIC CHEMISTRY, 2022, 59 (01) : 22 - 66
  • [74] Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?
    Shalini
    Kumar, Vipan
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (04) : 335 - 363
  • [75] Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer
    Shimomura, Iwao
    Yokoi, Akira
    Kohama, Isaku
    Kumazaki, Minami
    Tada, Yuji
    Tatsumi, Koichiro
    Ochiya, Takahiro
    Yamamoto, Yusuke
    [J]. CANCER LETTERS, 2019, 451 : 11 - 22
  • [76] Benzimidazole Scaffold as Anticancer Agent: Synthetic Approaches and Structure-Activity Relationship
    Shrivastava, Neelima
    Naim, Mohd. Javed
    Alam, Md. Jahangir
    Nawaz, Farah
    Ahmed, Shujauddin
    Alam, Ozair
    [J]. ARCHIV DER PHARMAZIE, 2017, 350 (06)
  • [77] Cancer statistics, 2022
    Siegel, Rebecca L.
    Miller, Kimberly D.
    Fuchs, Hannah E.
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2022, 72 (01) : 7 - 33
  • [78] Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids
    Singh, Ankit Kumar
    Kumar, Adarsh
    Singh, Harshwardhan
    Sonawane, Pankaj
    Paliwal, Harshali
    Thareja, Suresh
    Pathak, Prateek
    Grishina, Maria
    Jaremko, Mariusz
    Emwas, Abdul-Hamid
    Yadav, Jagat Pal
    Verma, Amita
    Khalilullah, Habibullah
    Kumar, Pradeep
    [J]. PHARMACEUTICALS, 2022, 15 (09)
  • [79] Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy
    Soltan, Osama M.
    Shoman, Mai E.
    Abdel-Aziz, Salah A.
    Narumi, Atsushi
    Konno, Hiroyuki
    Abdel-Aziz, Mohamed
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 225
  • [80] Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer
    Sparano, Joseph A.
    Moulder, Stacy
    Kazi, Aslamuzzaman
    Coppola, Domenico
    Negassa, Abdissa
    Vahdat, Linda
    Li, Tianhong
    Pellegrino, Christine
    Fineberg, Susan
    Munster, Pam
    Malafa, Mokenge
    Lee, David
    Hoschander, Shira
    Hopkins, Una
    Hershman, Dawn
    Wright, John J.
    Kleer, Celina
    Merajver, Sofia
    Sebti, Said M.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (08) : 2942 - 2948